Bright Minds Biosciences Dirección

Dirección controles de criterios 2/4

El CEO de Bright Minds Biosciences es Ian McDonald, nombrado en May 2019, tiene una permanencia de 5.5 años. posee directamente un 14.03% de las acciones de la empresa, con un valor de CA$48.16M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 2.5 años, respectivamente.

Información clave

Ian McDonald

Chief Executive Officer (CEO)

CA$626.2k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.5yrs
Participación del CEO	14.0%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.5yrs

Actualizaciones recientes de la dirección

Recent updates

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Oct 16

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

CEO

Ian McDonald (35 yo)

5.5yrs

Permanencia

CA$626,178

Compensación

Mr. Ian McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executive Officer since June 06, 2020 and serves as its President and Director since May 31, 2019. He served as Presi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ian McDonald	Co-Founder	5.5yrs	CA$626.18k	14.03% CA$ 48.2m
Ryan E. S. Cheung	Chief Financial Officer	4.5yrs	CA$120.00k	0% CA$ 0
Jan Pedersen	Chief Science Officer & Director	2.2yrs	CA$799.72k	sin datos
Mark Smith	Chief Medical Officer	1.9yrs	CA$505.51k	sin datos
Alex Vasilkevich	COO & VP of Corporate Development	less than a year	sin datos	0.28% CA$ 975.6k
Emer Leahy	Consultant	2.5yrs	sin datos	sin datos

2.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DRUG se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ian McDonald	Co-Founder	5.5yrs	CA$626.18k	14.03% CA$ 48.2m
Jan Pedersen	Chief Science Officer & Director	2.6yrs	CA$799.72k	sin datos
Robert Malenka	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos
Herbert Meltzer	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos
David Weiner	Independent Non-Executive Director	1.8yrs	CA$22.04k	sin datos
Jeremy Fryzuk	Independent Director	4.2yrs	CA$7.69k	2.79% CA$ 9.6m
Nils Bottler	Independent Director	4.2yrs	CA$7.69k	0.072% CA$ 247.0k
Michael Bogenschutz	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos
Peter Hendricks	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos

2.5yrs

Permanencia media

39yo

Promedio de edad

Junta con experiencia: La junta directiva de DRUG no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Bright Minds Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director exercised options to buy CA$1.0m worth of stock.

Independent Director exercised options to buy CA$1.1m worth of stock.

High number of new and inexperienced directors

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Recent updates

New major risk - Shareholder dilution

Independent Director exercised options to buy CA$1.0m worth of stock.

Bright Minds Biosciences Inc. announced that it has received $34.999973 million in funding from a group of investors

Independent Director exercised options to buy CA$1.1m worth of stock.

Bright Minds Biosciences Inc. announced that it expects to receive $35 million in funding

Bright Minds Biosciences Inc. Announces Positive Data from the Preclinical Testing of BMB-201

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study Using its Artificial Intelligence, FDA-Cleared BNA™? Technology

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

High number of new and inexperienced directors

New major risk - Financial position

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding

New major risk - Market cap size

Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101

Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101

Less than half of directors are independent

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Bright Minds Biosciences Inc., Annual General Meeting, Mar 24, 2023

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

Bright Minds Biosciences Inc. announced that it expects to receive CAD 2.05 million in funding

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer, Effective December 1, 2022

High number of new and inexperienced directors

Bright Minds Biosciences Announces Executive Changes

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Bright Minds Biosciences Announces Changes to Its Executive Leadership Team

High number of new and inexperienced directors

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Bright Minds Biosciences Provides Scientific Update on Its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

High number of new and inexperienced directors

Bright Minds Biosciences Inc. Provides Scientific Update

CEO & Director recently bought CA$116k worth of stock

Bright Minds Biosciences Inc., Annual General Meeting, May 18, 2021

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 25.00371 million.

Bright Minds Biosciences Inc. Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences Announces Scientific Advisory Team Appointment

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad